Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis - PubMed (original) (raw)
Review
Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
Vivette D D'Agati et al. Nat Rev Nephrol. 2016 Aug.
Abstract
The prevalence of obesity-related glomerulopathy is increasing in parallel with the worldwide obesity epidemic. Glomerular hypertrophy and adaptive focal segmental glomerulosclerosis define the condition pathologically. The glomerulus enlarges in response to obesity-induced increases in glomerular filtration rate, renal plasma flow, filtration fraction and tubular sodium reabsorption. Normal insulin/phosphatidylinositol 3-kinase/Akt and mTOR signalling are critical for podocyte hypertrophy and adaptation. Adipokines and ectopic lipid accumulation in the kidney promote insulin resistance of podocytes and maladaptive responses to cope with the mechanical forces of renal hyperfiltration. Although most patients have stable or slowly progressive proteinuria, up to one-third develop progressive renal failure and end-stage renal disease. Renin-angiotensin-aldosterone blockade is effective in the short-term but weight loss by hypocaloric diet or bariatric surgery has induced more consistent and dramatic antiproteinuric effects and reversal of hyperfiltration. Altered fatty acid and cholesterol metabolism are increasingly recognized as key mediators of renal lipid accumulation, inflammation, oxidative stress and fibrosis. Newer therapies directed to lipid metabolism, including SREBP antagonists, PPARα agonists, FXR and TGR5 agonists, and LXR agonists, hold therapeutic promise.
Similar articles
- Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment.
Xu T, Sheng Z, Yao L. Xu T, et al. Front Med. 2017 Sep;11(3):340-348. doi: 10.1007/s11684-017-0570-3. Epub 2017 Aug 8. Front Med. 2017. PMID: 28791668 Review. - Obesity-Related Glomerulopathy: A Latent Change in Obesity Requiring More Attention.
Yang S, Cao C, Deng T, Zhou Z. Yang S, et al. Kidney Blood Press Res. 2020;45(4):510-522. doi: 10.1159/000507784. Epub 2020 Jun 4. Kidney Blood Press Res. 2020. PMID: 32498064 Review. - Which Patients with Obesity Are at Risk for Renal Disease?
Sandino J, Luzardo L, Morales E, Praga M. Sandino J, et al. Nephron. 2021;145(6):595-603. doi: 10.1159/000513868. Epub 2021 Mar 5. Nephron. 2021. PMID: 33677441 Review. - The Fatty Kidney and Beyond: A Silent Epidemic.
Hti Lar Seng NS, Lohana P, Chandra S, Jim B. Hti Lar Seng NS, et al. Am J Med. 2023 Oct;136(10):965-974. doi: 10.1016/j.amjmed.2023.06.025. Epub 2023 Jul 13. Am J Med. 2023. PMID: 37451390 Review. - The Fatty Kidney: Obesity and Renal Disease.
Praga M, Morales E. Praga M, et al. Nephron. 2017;136(4):273-276. doi: 10.1159/000447674. Epub 2016 Jul 15. Nephron. 2017. PMID: 27414023 Review.
Cited by
- Integrated miRNA-mRNA Analysis Reveals Critical miRNAs and Targets in Diet-Induced Obesity-Related Glomerulopathy.
López-Martínez M, Armengol MP, Pey I, Farré X, Rodríguez-Martínez P, Ferrer M, Porrini E, Luis-Lima S, Díaz-Martín L, Rodríguez-Rodríguez AE, Cruz-Perera C, Alcalde M, Navarro-Díaz M. López-Martínez M, et al. Int J Mol Sci. 2024 Jun 11;25(12):6437. doi: 10.3390/ijms25126437. Int J Mol Sci. 2024. PMID: 38928144 Free PMC article. - Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis.
Lei L, Zhu T, Cui TJ, Liu Y, Hocher JG, Chen X, Zhang XM, Cai KW, Deng ZY, Wang XH, Tang C, Lin L, Reichetzeder C, Zheng ZH, Hocher B, Lu YP. Lei L, et al. Am J Physiol Cell Physiol. 2024 Oct 1;327(4):C994-C1011. doi: 10.1152/ajpcell.00367.2024. Epub 2024 Aug 26. Am J Physiol Cell Physiol. 2024. PMID: 39183639 Free PMC article. - Childhood Obesity: Insight into Kidney Involvement.
Carullo N, Zicarelli M, Michael A, Faga T, Battaglia Y, Pisani A, Perticone M, Costa D, Ielapi N, Coppolino G, Bolignano D, Serra R, Andreucci M. Carullo N, et al. Int J Mol Sci. 2023 Dec 12;24(24):17400. doi: 10.3390/ijms242417400. Int J Mol Sci. 2023. PMID: 38139229 Free PMC article. Review. - Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats.
Shields CA, Poudel B, McPherson KC, Brown AK, Ekperikpe US, Browning E, Sutton L, Cornelius DC, Williams JM. Shields CA, et al. Front Physiol. 2020 Sep 18;11:566403. doi: 10.3389/fphys.2020.566403. eCollection 2020. Front Physiol. 2020. PMID: 33071820 Free PMC article. - Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies.
Shah PP, Brady TM, Meyers KEC, O'Shaughnessy MM, Gibson KL, Srivastava T, Zee J, Cattran D, Tuttle KR, Gadegbeku C, Glenn D, Derebail V, Smith A, Wang CS, Gillespie BW, Bitzer M, Sethna CB. Shah PP, et al. Nephron. 2021;145(3):245-255. doi: 10.1159/000513869. Epub 2021 Mar 5. Nephron. 2021. PMID: 33677435 Free PMC article.
References
- JAMA. 2007 Nov 7;298(17):2038-47 - PubMed
- J Am Soc Nephrol. 2005 Oct;16(10):2953-66 - PubMed
- J Am Soc Nephrol. 2001 Jun;12(6):1211-7 - PubMed
- J Am Soc Nephrol. 2003 Sep;14(9):2255-63 - PubMed
- J Lipid Res. 2009 Feb;50(2):312-26 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous